Piper Sandler raised the firm’s price target on Teladoc (TDOC) to $13 from $11 and keeps an Overweight rating on the shares following a Fireside Chat with CEO Chuck Divita and CFO Mala Murthy. The firm believes CY24 chronic care headwinds are transitory and expects Integrated Care segment growth to return to mid-single digits after a transition year in CY25.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC: